Switch to:
Also traded in: Argentina, Brazil, Chile, France, Germany, Mexico, Romania, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.49
MRK's Cash to Debt is ranked lower than
74% of the 767 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.15 vs. MRK: 0.49 )
Ranked among companies with meaningful Cash to Debt only.
MRK' s Cash to Debt Range Over the Past 10 Years
Min: 0.32  Med: 0.68 Max: 2.45
Current: 0.49
0.32
2.45
Equity to Asset 0.45
MRK's Equity to Asset is ranked lower than
75% of the 665 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. MRK: 0.45 )
Ranked among companies with meaningful Equity to Asset only.
MRK' s Equity to Asset Range Over the Past 10 Years
Min: 0.34  Med: 0.44 Max: 0.53
Current: 0.45
0.34
0.53
Interest Coverage 10.88
MRK's Interest Coverage is ranked lower than
71% of the 621 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 98.90 vs. MRK: 10.88 )
Ranked among companies with meaningful Interest Coverage only.
MRK' s Interest Coverage Range Over the Past 10 Years
Min: 4.14  Med: 9.88 Max: 20.13
Current: 10.88
4.14
20.13
F-Score: 7
Z-Score: 3.43
M-Score: -2.68
WACC vs ROIC
6.59%
10.84%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 18.67
MRK's Operating margin (%) is ranked higher than
79% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.87 vs. MRK: 18.67 )
Ranked among companies with meaningful Operating margin (%) only.
MRK' s Operating margin (%) Range Over the Past 10 Years
Min: 6.43  Med: 16.45 Max: 21.86
Current: 18.67
6.43
21.86
Net-margin (%) 13.01
MRK's Net-margin (%) is ranked higher than
75% of the 717 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.15 vs. MRK: 13.01 )
Ranked among companies with meaningful Net-margin (%) only.
MRK' s Net-margin (%) Range Over the Past 10 Years
Min: 1.87  Med: 13.3 Max: 47.03
Current: 13.01
1.87
47.03
ROE (%) 11.46
MRK's ROE (%) is ranked higher than
64% of the 746 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.03 vs. MRK: 11.46 )
Ranked among companies with meaningful ROE (%) only.
MRK' s ROE (%) Range Over the Past 10 Years
Min: 1.51  Med: 14.91 Max: 42.27
Current: 11.46
1.51
42.27
ROA (%) 5.12
MRK's ROA (%) is ranked higher than
59% of the 774 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.71 vs. MRK: 5.12 )
Ranked among companies with meaningful ROA (%) only.
MRK' s ROA (%) Range Over the Past 10 Years
Min: 0.79  Med: 6.5 Max: 16.34
Current: 5.12
0.79
16.34
ROC (Joel Greenblatt) (%) 51.97
MRK's ROC (Joel Greenblatt) (%) is ranked higher than
84% of the 764 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.38 vs. MRK: 51.97 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MRK' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 10.88  Med: 43.35 Max: 105.49
Current: 51.97
10.88
105.49
Revenue Growth (3Y)(%) -3.30
MRK's Revenue Growth (3Y)(%) is ranked lower than
75% of the 601 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.60 vs. MRK: -3.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MRK' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -16.5  Med: 2.3 Max: 21.4
Current: -3.3
-16.5
21.4
EBITDA Growth (3Y)(%) -6.40
MRK's EBITDA Growth (3Y)(%) is ranked lower than
75% of the 555 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.20 vs. MRK: -6.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MRK' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -17.6  Med: -2 Max: 44.8
Current: -6.4
-17.6
44.8
EPS Growth (3Y)(%) -7.90
MRK's EPS Growth (3Y)(%) is ranked lower than
69% of the 522 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.20 vs. MRK: -7.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MRK' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -29.3  Med: 6.7 Max: 73.8
Current: -7.9
-29.3
73.8
» MRK's 10-Y Financials

Financials (Next Earnings Date: 2016-10-25)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

MRK Guru Trades in Q3 2015

Joel Greenblatt 5,844 sh (New)
Richard Snow 860,145 sh (+15902.70%)
Ray Dalio 251,746 sh (+1368.68%)
Paul Tudor Jones 44,663 sh (+164.28%)
PRIMECAP Management 2,645,000 sh (+29.53%)
Vanguard Health Care Fund 49,743,388 sh (+8.73%)
Murray Stahl 43,271 sh (+5.15%)
Pioneer Investments 3,427,061 sh (+4.51%)
Ruane Cunniff 4,994 sh (+4.39%)
Mairs and Power 104,124 sh (+1.22%)
Robert Bruce 259,400 sh (unchged)
David Carlson 250,000 sh (unchged)
First Eagle Investment 9,050 sh (unchged)
Prem Watsa 12,000 sh (unchged)
David Dreman Sold Out
Kyle Bass Sold Out
Tom Russo Sold Out
RS Investment Management Sold Out
Dodge & Cox 24,585,258 sh (-0.39%)
T Rowe Price Equity Income Fund 6,571,200 sh (-0.82%)
Charles Brandes 2,791,984 sh (-0.90%)
Kahn Brothers 1,006,208 sh (-1.02%)
Ken Fisher 6,761,706 sh (-1.09%)
Barrow, Hanley, Mewhinney & Strauss 25,179,076 sh (-1.80%)
Jeff Auxier 141,489 sh (-2.51%)
Manning & Napier Advisors, Inc 6,178,367 sh (-2.66%)
Mario Gabelli 142,715 sh (-3.92%)
Signature Select Canadian Fund 154,400 sh (-4.28%)
NWQ Managers 69,835 sh (-5.36%)
Jim Simons 1,461,734 sh (-23.94%)
Jeremy Grantham 4,200 sh (-35.38%)
» More
Q4 2015

MRK Guru Trades in Q4 2015

Tom Russo 3,836 sh (New)
John Buckingham 24,665 sh (New)
Joel Greenblatt 753,471 sh (+12793.07%)
Jim Simons 1,752,234 sh (+19.87%)
Richard Snow 998,514 sh (+16.09%)
Jeff Auxier 153,403 sh (+8.42%)
Charles Brandes 3,012,572 sh (+7.90%)
Barrow, Hanley, Mewhinney & Strauss 26,655,176 sh (+5.86%)
PRIMECAP Management 2,790,000 sh (+5.48%)
Vanguard Health Care Fund 50,476,700 sh (+1.47%)
Ken Fisher 6,822,070 sh (+0.89%)
Mairs and Power 104,637 sh (+0.49%)
Kahn Brothers 1,010,927 sh (+0.47%)
Robert Bruce 259,400 sh (unchged)
Ruane Cunniff 4,994 sh (unchged)
David Carlson 250,000 sh (unchged)
Jeremy Grantham 4,200 sh (unchged)
Prem Watsa Sold Out
Dodge & Cox 24,563,150 sh (-0.09%)
Murray Stahl 43,031 sh (-0.55%)
NWQ Managers 68,615 sh (-1.75%)
Mario Gabelli 139,615 sh (-2.17%)
Paul Tudor Jones 40,561 sh (-9.18%)
First Eagle Investment 7,790 sh (-13.92%)
T Rowe Price Equity Income Fund 5,610,000 sh (-14.63%)
Ray Dalio 156,246 sh (-37.94%)
Pioneer Investments 989,884 sh (-71.12%)
Manning & Napier Advisors, Inc 578,810 sh (-90.63%)
» More
Q1 2016

MRK Guru Trades in Q1 2016

Richard Pzena 921,365 sh (New)
David Dreman 710 sh (New)
John Burbank 1,370,117 sh (New)
Paul Tudor Jones 714,430 sh (+1661.37%)
First Eagle Investment 16,090 sh (+106.55%)
Joel Greenblatt 1,248,557 sh (+65.71%)
Ray Dalio 210,746 sh (+34.88%)
PRIMECAP Management 2,992,800 sh (+7.27%)
Murray Stahl 45,497 sh (+5.73%)
John Buckingham 25,885 sh (+4.95%)
Barrow, Hanley, Mewhinney & Strauss 26,663,511 sh (+0.03%)
David Carlson 250,000 sh (unchged)
Robert Bruce 259,400 sh (unchged)
Tom Russo 3,836 sh (unchged)
NWQ Managers Sold Out
Jeremy Grantham Sold Out
Jeff Auxier 153,303 sh (-0.07%)
Dodge & Cox 24,543,704 sh (-0.08%)
Charles Brandes 3,000,058 sh (-0.42%)
Ken Fisher 6,698,235 sh (-1.82%)
Ruane Cunniff 4,894 sh (-2.00%)
Kahn Brothers 985,419 sh (-2.52%)
Mairs and Power 101,850 sh (-2.66%)
Signature Select Canadian Fund 149,400 sh (-3.24%)
Vanguard Health Care Fund 48,728,100 sh (-3.46%)
Pioneer Investments 925,463 sh (-6.51%)
Richard Snow 911,027 sh (-8.76%)
Manning & Napier Advisors, Inc 501,558 sh (-13.35%)
Mario Gabelli 118,145 sh (-15.38%)
T Rowe Price Equity Income Fund 4,702,900 sh (-16.17%)
Jim Simons 484,334 sh (-72.36%)
» More
Q2 2016

MRK Guru Trades in Q2 2016

Tom Gayner 5,600 sh (New)
Jim Simons 2,926,534 sh (+504.24%)
Richard Pzena 1,415,390 sh (+53.62%)
Ray Dalio 251,546 sh (+19.36%)
Ken Fisher 6,759,345 sh (+0.91%)
Mairs and Power 102,164 sh (+0.31%)
Robert Bruce 259,400 sh (unchged)
David Dreman 710 sh (unchged)
David Carlson 250,000 sh (unchged)
Murray Stahl 45,497 sh (unchged)
Jeff Auxier 153,303 sh (unchged)
Tom Russo Sold Out
John Burbank Sold Out
Barrow, Hanley, Mewhinney & Strauss 26,516,070 sh (-0.55%)
Dodge & Cox 24,372,814 sh (-0.70%)
John Buckingham 25,676 sh (-0.81%)
PRIMECAP Management 2,967,700 sh (-0.84%)
Kahn Brothers 964,925 sh (-2.08%)
Pioneer Investments 901,916 sh (-2.54%)
Charles Brandes 2,891,914 sh (-3.60%)
Mario Gabelli 113,505 sh (-3.93%)
Vanguard Health Care Fund 46,499,820 sh (-4.57%)
Richard Snow 848,738 sh (-6.84%)
Ruane Cunniff 3,981 sh (-18.66%)
Manning & Napier Advisors, Inc 404,399 sh (-19.37%)
T Rowe Price Equity Income Fund 3,500,000 sh (-25.58%)
First Eagle Investment 7,790 sh (-51.58%)
Joel Greenblatt 540,222 sh (-56.73%)
Paul Tudor Jones 3,900 sh (-99.45%)
» More
» Details

Insider Trades

Latest Guru Trades with MRK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:NYSE:NVS, NYSE:PFE, NYSE:ABBV, OTCPK:GLAXF, NYSE:SNY, NYSE:BMY, OTCPK:BAYRY, NYSE:LLY, NYSE:AZN, OTCPK:SZUKF, OTCPK:ALPMY, OTCPK:OTSKY, NYSE:JNJ, OTCPK:CHGCY, OTCPK:DSNKY, OTCPK:OPHLY, OTCPK:KYKOF, OTCPK:PTKFF, OTCPK:CHPTY, OTCPK:SNPHY » details
Traded in other countries:MRK.Argentina, MRCK34.Brazil, MRK.Chile, MRK.France, 6MK.Germany, MRK.Mexico, MRK.Romania, MRK.Switzerland, 0QAH.UK,
Merck & Co Inc is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products.

Merck & Co Inc was incorporated in New Jersey in 1970. The Company is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. The Company's operations are managed on a products basis and are comprised of four operating segments, the Pharmaceutical, Animal Health, Alliances and Healthcare Services segments. The Pharmaceutical segment is the only reportable segment. The Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, administered at physician offices. The Company sells these human health vaccines to physicians, wholesalers, physician distributors and government entities. The Company also has animal health operations that discover, develop, manufacture and market animal health products, including vaccines, which the Company sells to veterinarians, distributors and animal producers. The Alliances segment includes results from the Company's relationship with AstraZeneca LP until the termination of that relationship on June 30, 2014. The Company's Healthcare Services segment provides services and solutions that focus on engagement, health analytics and clinical services to improve the value of care delivered to patients. The Company's pharmaceutical products include therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Products within the Company's franchises are - Primary Care and Women's Health include Cardiovascular, Diabetes, and General Medicine and Women's Health; Hospital and Specialty include Hepatitis, HIV, Hospital Acute Care, and Immunology; Oncology includes Keytruda, Emend, Temodar, and Temodal; Diversified Brands includes Respiratory and Others; and Vaccines. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines. Principal products in this segment include - Livestock Products; Poultry Products; Companion Animal Products; and Aquaculture Products. The Company's competitors include other research-based pharmaceutical companies, smaller research companies with more limited therapeutic focus, generic drug manufacturers and animal health care companies.

Ratios

vs
industry
vs
history
P/E(ttm) 34.66
MRK's P/E(ttm) is ranked lower than
61% of the 535 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.55 vs. MRK: 34.66 )
Ranked among companies with meaningful P/E(ttm) only.
MRK' s P/E(ttm) Range Over the Past 10 Years
Min: 6.33  Med: 20.07 Max: 138.33
Current: 34.66
6.33
138.33
Forward P/E 16.75
MRK's Forward P/E is ranked higher than
55% of the 65 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.89 vs. MRK: 16.75 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 34.66
MRK's PE(NRI) is ranked lower than
61% of the 535 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.41 vs. MRK: 34.66 )
Ranked among companies with meaningful PE(NRI) only.
MRK' s PE(NRI) Range Over the Past 10 Years
Min: 6.33  Med: 20.07 Max: 138.33
Current: 34.66
6.33
138.33
Price/Owner Earnings (ttm) 22.83
MRK's Price/Owner Earnings (ttm) is ranked higher than
68% of the 279 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.58 vs. MRK: 22.83 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
MRK' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 6.1  Med: 15.72 Max: 48.31
Current: 22.83
6.1
48.31
P/B 3.98
MRK's P/B is ranked lower than
63% of the 690 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.04 vs. MRK: 3.98 )
Ranked among companies with meaningful P/B only.
MRK' s P/B Range Over the Past 10 Years
Min: 1.72  Med: 3.22 Max: 7.25
Current: 3.98
1.72
7.25
P/S 4.49
MRK's P/S is ranked lower than
65% of the 690 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.78 vs. MRK: 4.49 )
Ranked among companies with meaningful P/S only.
MRK' s P/S Range Over the Past 10 Years
Min: 2.02  Med: 3.26 Max: 5.48
Current: 4.49
2.02
5.48
PFCF 18.21
MRK's PFCF is ranked higher than
68% of the 192 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.70 vs. MRK: 18.21 )
Ranked among companies with meaningful PFCF only.
MRK' s PFCF Range Over the Past 10 Years
Min: 7.87  Med: 16 Max: 88.93
Current: 18.21
7.87
88.93
POCF 15.81
MRK's POCF is ranked higher than
54% of the 248 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.32 vs. MRK: 15.81 )
Ranked among companies with meaningful POCF only.
MRK' s POCF Range Over the Past 10 Years
Min: 6.67  Med: 13.22 Max: 35.85
Current: 15.81
6.67
35.85
EV-to-EBIT 26.49
MRK's EV-to-EBIT is ranked lower than
60% of the 524 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.32 vs. MRK: 26.49 )
Ranked among companies with meaningful EV-to-EBIT only.
MRK' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.9  Med: 14.4 Max: 52.6
Current: 26.49
4.9
52.6
EV-to-EBITDA 14.02
MRK's EV-to-EBITDA is ranked higher than
61% of the 552 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.57 vs. MRK: 14.02 )
Ranked among companies with meaningful EV-to-EBITDA only.
MRK' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.2  Med: 8.6 Max: 20.4
Current: 14.02
4.2
20.4
PEG 3.77
MRK's PEG is ranked lower than
69% of the 289 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.98 vs. MRK: 3.77 )
Ranked among companies with meaningful PEG only.
MRK' s PEG Range Over the Past 10 Years
Min: 0.52  Med: 2.72 Max: 28.55
Current: 3.77
0.52
28.55
Shiller P/E 27.86
MRK's Shiller P/E is ranked higher than
76% of the 154 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 51.01 vs. MRK: 27.86 )
Ranked among companies with meaningful Shiller P/E only.
MRK' s Shiller P/E Range Over the Past 10 Years
Min: 8.27  Med: 16.39 Max: 28.26
Current: 27.86
8.27
28.26
Current Ratio 1.87
MRK's Current Ratio is ranked lower than
61% of the 672 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. MRK: 1.87 )
Ranked among companies with meaningful Current Ratio only.
MRK' s Current Ratio Range Over the Past 10 Years
Min: 1.07  Med: 1.59 Max: 3.7
Current: 1.87
1.07
3.7
Quick Ratio 1.44
MRK's Quick Ratio is ranked lower than
61% of the 672 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.80 vs. MRK: 1.44 )
Ranked among companies with meaningful Quick Ratio only.
MRK' s Quick Ratio Range Over the Past 10 Years
Min: 0.8  Med: 1.28 Max: 3.44
Current: 1.44
0.8
3.44
Days Inventory 131.92
MRK's Days Inventory is ranked lower than
60% of the 674 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.20 vs. MRK: 131.92 )
Ranked among companies with meaningful Days Inventory only.
MRK' s Days Inventory Range Over the Past 10 Years
Min: 104.23  Med: 130.49 Max: 205.16
Current: 131.92
104.23
205.16
Days Sales Outstanding 64.00
MRK's Days Sales Outstanding is ranked higher than
60% of the 577 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.29 vs. MRK: 64.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
MRK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.5  Med: 58.77 Max: 87.87
Current: 64
44.5
87.87
Days Payable 62.16
MRK's Days Payable is ranked lower than
55% of the 527 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 67.16 vs. MRK: 62.16 )
Ranked among companies with meaningful Days Payable only.
MRK' s Days Payable Range Over the Past 10 Years
Min: 30.2  Med: 44.78 Max: 90.81
Current: 62.16
30.2
90.81

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.90
MRK's Dividend Yield is ranked higher than
78% of the 610 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.57 vs. MRK: 2.90 )
Ranked among companies with meaningful Dividend Yield only.
MRK' s Dividend Yield Range Over the Past 10 Years
Min: 2.51  Med: 3.81 Max: 6.68
Current: 2.9
2.51
6.68
Dividend Payout 1.01
MRK's Dividend Payout is ranked lower than
82% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.34 vs. MRK: 1.01 )
Ranked among companies with meaningful Dividend Payout only.
MRK' s Dividend Payout Range Over the Past 10 Years
Min: 0.15  Med: 0.52 Max: 4.22
Current: 1.01
0.15
4.22
Dividend Growth (3y) 2.30
MRK's Dividend Growth (3y) is ranked lower than
62% of the 291 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. MRK: 2.30 )
Ranked among companies with meaningful Dividend Growth (3y) only.
MRK' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 2.8 Max: 14.8
Current: 2.3
0
14.8
Forward Dividend Yield 2.93
MRK's Forward Dividend Yield is ranked higher than
79% of the 586 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.62 vs. MRK: 2.93 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 3.48
MRK's Yield on cost (5-Year) is ranked higher than
72% of the 717 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.13 vs. MRK: 3.48 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
MRK' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 3.01  Med: 4.57 Max: 8.01
Current: 3.48
3.01
8.01
3-Year Average Share Buyback Ratio 2.80
MRK's 3-Year Average Share Buyback Ratio is ranked higher than
97% of the 424 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.40 vs. MRK: 2.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MRK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -13  Med: 1.1 Max: 2.8
Current: 2.8
-13
2.8

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 33.22
MRK's Price/Tangible Book is ranked lower than
96% of the 642 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.78 vs. MRK: 33.22 )
Ranked among companies with meaningful Price/Tangible Book only.
MRK' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.19  Med: 12.79 Max: 3112.5
Current: 33.22
3.19
3112.5
Price/Projected FCF 1.46
MRK's Price/Projected FCF is ranked higher than
71% of the 299 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.42 vs. MRK: 1.46 )
Ranked among companies with meaningful Price/Projected FCF only.
MRK' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.75  Med: 1.23 Max: 3.04
Current: 1.46
0.75
3.04
Price/Median PS Value 1.38
MRK's Price/Median PS Value is ranked lower than
62% of the 651 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.15 vs. MRK: 1.38 )
Ranked among companies with meaningful Price/Median PS Value only.
MRK' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.65  Med: 1.21 Max: 2
Current: 1.38
0.65
2
Price/Peter Lynch Fair Value 5.76
MRK's Price/Peter Lynch Fair Value is ranked lower than
91% of the 152 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.51 vs. MRK: 5.76 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
MRK' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.55  Med: 1.64 Max: 10.48
Current: 5.76
0.55
10.48
Price/Graham Number 7.15
MRK's Price/Graham Number is ranked lower than
90% of the 400 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.35 vs. MRK: 7.15 )
Ranked among companies with meaningful Price/Graham Number only.
MRK' s Price/Graham Number Range Over the Past 10 Years
Min: 1.09  Med: 3.93 Max: 31.92
Current: 7.15
1.09
31.92
Earnings Yield (Greenblatt) (%) 3.81
MRK's Earnings Yield (Greenblatt) (%) is ranked higher than
58% of the 742 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. MRK: 3.81 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MRK' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.9  Med: 6.9 Max: 20.6
Current: 3.81
1.9
20.6
Forward Rate of Return (Yacktman) (%) 10.84
MRK's Forward Rate of Return (Yacktman) (%) is ranked higher than
56% of the 331 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.18 vs. MRK: 10.84 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MRK' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -5.7  Med: 6.7 Max: 22.2
Current: 10.84
-5.7
22.2

More Statistics

Revenue (TTM) (Mil) $39,444
EPS (TTM) $ 1.81
Beta0.75
Short Percentage of Float1.13%
52-Week Range $47.97 - 64.00
Shares Outstanding (Mil)2,765.21

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 39,576 39,307 40,937
EPS ($) 3.74 3.84 4.09
EPS w/o NRI ($) 3.74 3.84 4.09
EPS Growth Rate
(3Y to 5Y Estimate)
4.41%
Dividends Per Share ($) 1.82 1.84 1.86
» More Articles for NYSE:MRK

Headlines

Articles On GuruFocus.com
Gilead Was Smart to Let Medivation Slip Through its Fingers Aug 29 2016 
Pharmaceuticals are the New Bonds Aug 30 2016 
Tight Trading on Thursday with Stocks Ending Lower Aug 25 2016 
Healthcare Drug Pricing a Factor for the Market on Wednesday Aug 24 2016 
Merck Offers Value and Steady Dividend Growth Aug 24 2016 
Merck: Biotech and Pharmaceuticals Giant Aug 12 2016 
U.S. Market Indexes Higher on Thursday with Positive Retail Reports Aug 11 2016 
US Market Indexes Close Lower on Monday Aug 08 2016 
U.S. Market Indexes Higher After Positive Jobs Report Aug 08 2016 
Revenue and Earnings Higher for Merck in the Second Quarter Aug 02 2016 

More From Other Websites
Medivation Proxy Shows Pfizer Battled Four Bidders to Seal a Deal Aug 31 2016
This Pharma Company Is Leading The Race For A Zika Vaccine Aug 30 2016
Merck KGaA -- Moody's changes outlook on Merck KGaA's ratings to stable from negative; affirms... Aug 30 2016
Time to Shift Your Focus Aug 28 2016
Saturday links: bad intentions Aug 27 2016
Lung cancer doctors eye Merck's Keytruda over Bristol's Opdivo Aug 25 2016
Merck Offers Value and Steady Dividend Growth Aug 24 2016
Health-care sector trails broader market as pricing issues reinflamed Aug 24 2016
Merck Potential Blockbuster Drug, Key Acquisition Make It a Good Bet for Investors Aug 23 2016
[$$] Pfizer’s Medivation Deal Latest in Long Line of Similar Acquisitions Aug 22 2016
Monday links: work and drudgery Aug 22 2016
[$$] Pfizer's Medivation Deal Latest in Long Line of Similar Acquisitions Aug 22 2016
Pfizer Will Buy Cancer Drugmaker Medivation For $14 Billion Aug 22 2016
Curbing Excessive Exuberance May be Premature Aug 21 2016
How Much Medivation Can Really Fetch in a Buyout Aug 18 2016
Merck Among Drug Giants Looking To Buy Medivation, Says Report Aug 17 2016
Gilead Sciences: Still Dominating Hepatitis C But… Aug 17 2016
How Will Merck (MRK) Stock React to Potential Medivation Bid? Aug 17 2016
How Did Merck’s Animal Health Segment Perform? Aug 17 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)